Systemic sclerosis & Raynaud's
Mobilization with reduced cyclophosphamide for autologous stem cell transplantation is feasible in patients with systemic sclerosis
Authors' conclusion
Our data demonstrate that a reduced cyclophosphamide mobilization regimen seems to be feasible.
Study context
- Population
- Patients with SSc who underwent autologous stem cell transplantation
- Participants
- 32 patients
- Exposure
- Low dose vs high dose cyclophosphamide for stem cell mobilization
- Outcome
- Occurrence of 'poor mobilization' with different CYC dosing
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Stem cell yield after CD34+ enrichment
Observational data: associations, not effects.
Further findings
Risk factors for poor stem cell collection, independent of regimen
- Lower bodyweight and BMI
- P < 0.001
- Rituximab pre-therapy
- P < 0.05
- Cardiac involvement
- P < 0.01
Original publication
Mobilization with reduced cyclophosphamide for autologous stem cell transplantation is feasible in patients with systemic sclerosis. Rheumatology (Oxford). Published 11 August 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →